CELLCEUTIX, Inc. (NASDAQOTH:CTIX)

CAPS Rating: 1 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar BooDog2 (< 20) Submitted: 5/6/2015 1:18:45 PM : Outperform Start Price: $2.42 CTIX Score: +19.24

$CTIX Setting up as a bounce play from long term support. Pending up list to NASDAQ CM. Quite the pipeline with expansion already planned for Kevetrin. Do your DD.

Recs

0
Member Avatar MMCapitalMgmt (99.87) Submitted: 12/3/2014 11:39:18 AM : Underperform Start Price: $3.44 CTIX Score: +16.56

lol

Recs

0
Member Avatar SmartAce (99.89) Submitted: 9/22/2014 3:57:41 PM : Underperform Start Price: $2.33 CTIX Score: -20.66

Yo 148, 3-to-the-3-to-the-6-to-the-9.

Recs

0
Member Avatar eyezie1 (39.12) Submitted: 4/9/2014 2:47:04 AM : Outperform Start Price: $1.57 CTIX Score: +71.94

Brilacidin is a competitor of Cubist and Durata for use in gram positive infections. FDA is fast tracking antibiotics.

Recs

0
Member Avatar adi101 (89.78) Submitted: 3/2/2014 7:45:11 AM : Outperform Start Price: $1.95 CTIX Score: +35.39

clinical stage, 3 drugs in development: new antibiotic, anti psoriasis, cancer drug.

Recs

0
Member Avatar kmac28 (< 20) Submitted: 12/9/2013 6:49:02 AM : Outperform Start Price: $1.62 CTIX Score: +63.67

Fully dependent on current FDA trials at Dana Farber Cancer institute in MA.

Recs

0
Member Avatar jed71 (98.71) Submitted: 9/12/2013 11:38:55 AM : Underperform Start Price: $1.97 CTIX Score: -23.44

Pump N Dump scam.

Results 1 - 7 of 7

Featured Broker Partners


Advertisement